Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug Pricing Evolution in Hepatitis C.

PloS one - 1 Jan 2016

Vernaz Nathalie, Girardin François, Goossens Nicolas, Brügger Urs, Riguzzi Marco, Perrier Arnaud, Negro Francesco

Abstract excerpt

OBJECTIVE: We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the following five steps in the development of HCV treatment regimens: 1) interferon (IFN)-α monotherapy in the early '90s,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Discovery
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Ribavirin

Share to Ritonavir

Share to Sofosbuvir

Share to Switzerland

Source

Open in PubMed Open full text

Identifiers

PMID: 27310294
DOI: 10.1371/journal.pone.0157098
PMCID: PMC4911078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug Pricing Evolution in Hepatitis C.PMID 27310294Read ↗

The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.Semantic proximity Read ↗

Estimated global cost of treating COVID-19, HIV, Hepatitis B and Hepatitis C with approved effective oral medicationsSemantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.Semantic proximity Read ↗

Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.Semantic proximity Read ↗

Shining a light in the black box of orphan drug pricingSemantic proximity Read ↗

The direct-medical costs associated with interferon-based treatment for Hepatitis C in VietnamSemantic proximity Read ↗

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Semantic proximity Read ↗

Prices versus costs of production for molnupiravir as a COVID-19 treatmentSemantic proximity Read ↗

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Applying the Efficiency Frontier to Inform Value-Based Pricing for Gaucher Disease Therapies in BrazilSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.